https://www.england.nhs.uk/publication/methods-national-clinical-policies/<\/a><\/p>The voluntary scheme agreed between Department and the Association of the British Pharmaceutical Industry on getting the best value and most effective medicines into use more quickly for branded medicines pricing and access was published in November 2018. The voluntary scheme started on 1 January 2019 and will be in place for five years until 2023.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "277724"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:50:58.65Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Medical Treatments"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential effect of the closure of the Commissioning Support Programme on treatments within NHS England\u2019s Clinical Commissioning Policy programme; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277725"}
, {"_about" : "http://data.parliament.uk/resources/1139371", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139371/answer", "answerText" : {"_value" : "
Women at high risk of contracting HIV are already eligible to participate in the Pre-Exposure Prophylaxis Impact Trial.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:43:55.213Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "HIV Infection: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, whether his Department plans to include women who are at risk of contracting HIV in the PrEP impact trial.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277726"}
, {"_about" : "http://data.parliament.uk/resources/1139373", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139373/answer", "answerText" : {"_value" : "
The National Health Service is working closely with voluntary sector partners to improve patient outcomes for those with severe asthma and an NHS Cardiovascular Disease-Respiratory national programme has been developed in line with recommendations from the Taskforce for Lung Health.<\/p>
Both respiratory disease and the health of children and young people are priority areas in the NHS Long Term Plan, which aims to improve respiratory care through earlier diagnosis and increased access to treatments. The Respiratory Delivery Board will take forward respiratory proposals set out in the Plan, while the Children\u2019s Transformation Board will oversee work to review national asthma policy and existing clinical guidelines.<\/p>
The current quality outcomes framework indicators for asthma are in consultation and changes for the annual review indicators may include data on asthma control; exacerbations; and written personalised action plans. NHS RightCare will be publishing an asthma toolkit later this year to support local commissioners and systems in delivering quality care. A best practice tariff for asthma, which aims to reduce variation in asthma care, is also in development.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:14:08.823Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps his Department is taking in response to the death of Ella Kissi-Debrah to (a) improve asthma care and (b) monitor and reduce the effect of air pollution on asthma outcomes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277728"}
, {"_about" : "http://data.parliament.uk/resources/1139376", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139376/answer", "answerText" : {"_value" : "
It is expected that National Health Service patients with severe asthma are referred to their specialist asthma service where they will receive appropriate investigation and treatment. All specialised providers are required to develop a networked model of care as the vehicle for delivering an optimal pathway and maximising patient outcomes and experience. All specialised services report against national quality metrics for severe asthma services on an annual basis. Commissioner action is initiated with individual hospitals to address significant issues.<\/p>
The NHS England Specialised Commissioning team is running a severe asthma collaborative project to improve patient experience, outcomes and safety through improved access to specialist multidisciplinary teams for assessment and review.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "277748"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:22:50.54Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that asthma sufferers are referred for specialist treatment.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277729"}
, {"_about" : "http://data.parliament.uk/resources/1139377", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139377/answer", "answerText" : {"_value" : "
The NHS Long Term Plan has committed to improving outcomes for those with respiratory disease in England to match, or exceed, our international counterparts. To achieve this, the National Health Service is working closely with voluntary sector partners to improve patient outcomes for those with severe asthma and an National Health Service Cardiovascular Disease-Respiratory national programme has been developed in line with recommendations from the Taskforce for Lung Health.<\/p>
The NHS England Specialised Commissioning team is running a severe asthma collaborative project to improve patient experience, outcomes and safety through improved access to specialist multidisciplinary teams for assessment and review. All specialised providers are required to develop a networked model of care as the vehicle for delivering an optimal pathway and maximising patient outcomes and experience. All specialised services report against national quality metrics for severe asthma services on an annual basis. Commissioner action is initiated with individual hospitals to address significant issues.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:10:56.207Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 June 2019 to Question 257660 on Asthma: Health Services, what assessment he has made of the effectiveness of NHS treatment for people with severe asthma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277730"}
, {"_about" : "http://data.parliament.uk/resources/1139378", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139378/answer", "answerText" : {"_value" : "
There are currently 14 severe asthma centres in England. There are no plans to increase the number of centres, as severe asthma collaborative networks will improve severe asthma care within localities. All specialist providers are required to develop a networked model of care as the vehicle for delivering an optimal pathway and maximising patient outcomes and experience.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:11:44.403Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Health Services"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what plans he has to increase the number of severe asthma centres.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277731"}
, {"_about" : "http://data.parliament.uk/resources/1139379", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139379/answer", "answerText" : {"_value" : "
The Medicines and Healthcare products Regulatory Agency is responsible for monitoring the safety of all healthcare products in the United Kingdom, including short-acting beta agonists and oral corticosteroids to treat asthma. They receive information about safety issues from patients and clinicians through the Yellow Card Scheme. They review the product if necessary and take action to minimise risk and maximise benefit to the patients. Decisions about prescribing rest with the doctor or other prescriber who has clinical responsibility for the particular aspect of a patient\u2019s care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "277733"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:12:37.987Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Beta Agonists: Safety"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to monitor the safety of the prescription of short-acting beta agonists.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277732"}
, {"_about" : "http://data.parliament.uk/resources/1139380", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139380/answer", "answerText" : {"_value" : "
The Medicines and Healthcare products Regulatory Agency is responsible for monitoring the safety of all healthcare products in the United Kingdom, including short-acting beta agonists and oral corticosteroids to treat asthma. They receive information about safety issues from patients and clinicians through the Yellow Card Scheme. They review the product if necessary and take action to minimise risk and maximise benefit to the patients. Decisions about prescribing rest with the doctor or other prescriber who has clinical responsibility for the particular aspect of a patient\u2019s care.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-26", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "277732"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-26T11:12:38.033Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Asthma: Steroid Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to monitor the safe prescription of oral corticosteroids to treat asthma.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277733"}
, {"_about" : "http://data.parliament.uk/resources/1139381", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1139381/answer", "answerText" : {"_value" : "
The National Cervical Screening Programme is planning to publish its updated national guidance on colposcopy and programme management, which will include the management of CIN2 cervical cell changes in England, later this year.<\/p>
The guidance will bring together robust published evidence and current clinical practice to help provide a national consensus on this matter.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"}
}
, "answeringMemberConstituency" : {"_value" : "South Ribble"}
, "answeringMemberPrinted" : {"_value" : "Seema Kennedy"}
, "dateOfAnswer" : {"_value" : "2019-07-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-07-23T16:49:49.603Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-07-16", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Cervical Cancer: Research"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will take steps to establish a medical consensus on the management of CIN2 cervical cell changes.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4131", "label" : {"_value" : "Biography information for Jim Shannon"}
}
, "tablingMemberConstituency" : {"_value" : "Strangford"}
, "tablingMemberPrinted" : [{"_value" : "Jim Shannon"}
], "uin" : "277734"}
], "itemsPerPage" : 10, "next" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=1&min-answer.questionFirstAnswered.=2019-04-08T15%3A26%3A41.297Z&tablingMemberConstituency=Strangford&answer.answeringMemberPrinted=Seema+Kennedy", "page" : 0, "startIndex" : 1, "totalResults" : 79, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}